News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
FDA Warns of Birth Defects with Use of Johnson & Johnson’s Topamax
March 7, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - An epilepsy drug also used to help prevent migraines can increase the risk for oral birth defects in babies born to women taking the medication, U.S. health officials said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Women’s health
Biotech Leaders, Investors Ask FDA to Maintain Access to Mifepristone
July 3, 2025
·
2 min read
·
Tristan Manalac
Legal
Court Suspends Mass Layoffs at HHS, Rules Staff Cuts Likely Unlawful
July 2, 2025
·
2 min read
·
Tristan Manalac
Government
RFK Jr. Eyes Changes to Vaccine Injury Compensation Program
July 2, 2025
·
2 min read
·
Tristan Manalac
Government
100+ CEOs, Biopharma Leaders Sound Alarm on ‘Catastrophic’ Health Cuts
June 30, 2025
·
2 min read
·
Tristan Manalac